A Multicenter Phase II Trial of Ruxolitinib for Treatment of Corticosteroid Refractory Sclerotic Chronic Graft-Versus-Host Disease
Journal of Clinical Oncology · 2024
DOI: 10.1200/jco.24.00205 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Journal of Clinical Oncology, 2024. Verfasst von Vijaya Raj Bhatt und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology-Oncology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE. Hauptthemen laut MEDLINE: Adrenal Cortex Hormones, Graft vs Host Disease, Nitriles, Pyrazoles. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAAA NIH HHS, NCI NIH HHS, NIGMS NIH HHS.
Abstract (Originalsprache)
PURPOSE Sclerotic chronic graft-versus-host disease (cGVHD) represents a highly morbid and refractory form of cGVHD, and novel therapies for sclerotic cGVHD are critically needed. This study aimed to determine the efficacy of ruxolitinib in patients with corticosteroid refractory sclerotic cGVHD. PATIENTS AND METHODS In a single-arm multicenter phase II trial (N = 47), adults with sclerotic cGVHD refractory to corticosteroids and ≥one additional line of systemic therapy for cGVHD received ruxolitinib for ≥six months (ClinicalTrials.gov identifier: NCT03616184 ). The primary end point was complete or partial response (PR) in skin and/or joint defined according to the 2014 National Institute of Health cGVHD Consensus Criteria. RESULTS Following the use of ruxolitinib for a median of 11 months, PR in skin and/or joints was noted in 49% (95% CI, 34 to 64) at 6 months, with 45% having joint and fascia response and 19% having skin response. The duration of skin/joint response was 77% (95% CI, 48 to 91) at 12 months. Overall cGVHD PR was noted in 47% (95% CI, 32 to 61). Improvement in Lee Symptom Scale summary and skin subscale scores was noted in 38% of patients. With a cumulative incidence of treatment failure of 20.8% (95% CI, 10.0 to 34.1), nonrelapse mortality (NRM) of 2.2% (95% CI, 0.17 to 10.3), and no recurrent malignancy, failure-free survival (FFS) was 77.1% (95% CI, 61.3 to 87.0) at 12 months. Ruxolitinib was overall well tolerated with no new safety signals. CONCLUSION The use of ruxolitinib was associated with relatively high rates of skin/joint responses and overall cGVHD responses, improvement in patient-reported outcomes, low NRM, and high FFS in patients with refractory sclerotic cGVHD. Ruxolitinib offers an effective treatment option for refractory sclerotic cGVHD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Hematology-Oncology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE.
- Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE.
- Department of Biostatistics, University of Nebraska Medical Center, Omaha, NE.
- Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, OH.
- Blood and Marrow Transplant Program, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH.
- Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE.
ORCID-Profile: Vijaya Raj Bhatt, Hannah K Choe, Betty K Hamilton, Krishna Gundabolu, Lynette M Smith, Taiga Nishihori, Stephanie J Lee
Förderung
- NIAAA NIH HHS
- NCI NIH HHS
- NIGMS NIH HHS
Zitieren
APA
Bhatt, V. R., Shostrom, V. K., Choe, H. K., Hamilton, B. K., Gundabolu, K., Maness, L. J., Kumar, V., Mahato, R. I., Smith, L. M., Nishihori, T., & Lee, S. J. (2024). A Multicenter Phase II Trial of Ruxolitinib for Treatment of Corticosteroid Refractory Sclerotic Chronic Graft-Versus-Host Disease. Journal of Clinical Oncology. https://doi.org/10.1200/jco.24.00205
Vancouver
Bhatt VR, Shostrom VK, Choe HK, Hamilton BK, Gundabolu K, Maness LJ, et al. A Multicenter Phase II Trial of Ruxolitinib for Treatment of Corticosteroid Refractory Sclerotic Chronic Graft-Versus-Host Disease. Journal of Clinical Oncology. 2024. doi:10.1200/jco.24.00205
BibTeX
@article{Bhatt2024,
author = {Bhatt, Vijaya Raj and Shostrom, Valerie K and Choe, Hannah K and Hamilton, Betty K and Gundabolu, Krishna and Maness, Lori J and Kumar, Virender and Mahato, Ram I and Smith, Lynette M and Nishihori, Taiga and Lee, Stephanie J},
title = {A Multicenter Phase II Trial of Ruxolitinib for Treatment of Corticosteroid Refractory Sclerotic Chronic Graft-Versus-Host Disease},
journal = {Journal of Clinical Oncology},
year = {2024},
doi = {10.1200/jco.24.00205}
}
EUVIMED